Keflex
Every registration of this product has been cancelled.
(6R,7R)-7-[[(2R)-2-Amino-2-phenylacetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 27447.
Registration
- Applicants
- 1
- Registrations
- 2
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| Pharmacare limited û woodmeadCancelled | Keflex | 250, 500 | B0092, C0220 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Keflex 250 EACH CAPSULE CONTAINS CEPHALEXIN 250 mg | 250 | B0092B/20.1.1/92 | Cancelled | Not determined | None |
| Keflex 500 EACH TABLET CONTAINS CEPHALEXIN MONOHYDRATE EQUIVALENT TO 500 mg CEPHALEXIN | 500 | C0220C/20.1.1/220 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.